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Abstract 
We have developed a system for studying hepatocellular growth potential in which liver cells are introduced into 
the diseased livers of Fah-/-; Scid/Scid double knockout mice. To use this system to study cell transplantation, 
DsRed  liver cells were introduced into severe immunodeficient Fah-/-; Scid/Scid double knockout  mice. In 
regenerated recipient livers, up to 20% of the mouse liver is repopulated by DsRed mouse hepatocytes 
demonstrating the creation of a functional mouse liver in which parenchyma is derived from DsRed mouse 
hepatocytes. The severe immunodeficient Fah-/-;Scid/Scid double knockout mice provide a tool for studying 
hepatocellular biology.  
Keywords: Human Hepatocytes, Transplantation, DsRed and Fah-/-;Scid/Scid Mice. 
 
1. Introduction 
In vitro cultures of primary cells often do not reflect their biological functions in the organism. For instance, 
cultured human hepatocytes display a different gene expression profile than hepatocytes in the liver. Therefore, 
substantial efforts have been made to repopulate murine livers with human hepatocytes. Yet the ability to 
propagate specialized human cells with intact biological functions in experimental animal models remains 
technically challenging. Until recently, only the urokinase type plasminogen activator (uPA) mouse model was 
permissive for repopulation of human hepatocytes. This mouse model, developed to study bleeding disorders, 
contains an additional copy of uPAexpressed from an albumin promoter. As anticipated, the mouse had 
increased fibrinolysis, but hepatotoxicity was also observed, which usually led to the death of pups because of 
intestinal bleeding or liver failure1. A few years later, congenic and xenogenic (rat and woodchuck) hepatocyte 
transplantation was reported2–4. Jonathana A. Rhim et al. have developed a transgenic mouse system to assess the 
regenerative capacity of hepatocytes. In this system, albuminurokinase (Alb-uPA) transgenic mice are recipients 
of donor mouse hepatocytes. The transplanted hepatocytes grow within the Alb-uPA liver4, replacing transgene-
expressing hepatocytes that are functionally compromised by transgene expression1. Using this approach, they 
demonstrated that hepatocytes from adult liver have extensive replicative potential4. The growth of the 
transplanted cells was occurred over several weeks. The resulting fully regenerated livers were chimeric, 
composed both of donor-derived cells and of host-derived cells that had deleted transgene DNA and therefore no 
longer expressed the transgene4. Like transplanted hepatocytes, these host-derived cells also had a growth 
advantage relative to transgene-expressing hepatocytes and expanded. In hemizygous transgenic animals, 
transgene inactivation is a relatively frequent event1; complete replacement of the transgenic liver occurs by 8 
weeks of age. By comparison, in homozygous mice, transgene inactivation is a less common event, consistent 
with the fact that two transgene arrays must be inactivated. Thus, hepatocyte transfer into homozygous Alb-uPA 
mice would be ideal for assessing liver cell growth. Even though Alb-uPA transgenic mouse liver supported the 
growth of transplanted mouse hepatocytes4  but this mouse model was immunotolerant. So, we hypothesized that 
immunodeficient mice with lacking the enzyme fumarylacetoacetate hydrolase (Fah-/-) would be better model to 
assess the growth of transplanted hepatocytes from other types of  mouse or species. That’s why we generated 
Fah-/-; Scid/Scid double knockout mice and successfully transplanted hepatocytes from DsRed mouse. We have 
shown that upto 20% of diseased mouse liver hepatocytes were replaced by hepatocytes from donor mice DsRed. 
This study supports the previous study of Karl-Dimiter B. et al.5  Finally, if our current methods were feasible, 
Fah-/-; Scid/Scid double knockout mice livers repopulated with hepatocytes  from dsRed mice would be valuable 
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tools for studying liver biology and in near future these mice would be in vivo model systems for receiving 
human hepatocytes. 
  
2. Materials and Methods 
Mice: The Fah-/- mouse6 was crossed with the mice homozygous for the severe combined immune deficiency 
spontaneous mutation Prkdcscid, commonly referred to as scid, are characterized by an absence of functional T 
cells and B cells. These mice were obtained from The Jackson Laboratory. Homozygous mice were identified by 
genotyping of tail DNA. Genotyping was done with the same primers and conditions as described elsewhere6 or 
according to the protocols provided by vendors. The severe immunodeficient Fah-/-; Scid/Scid double knockout 
mice were kept on 7.5 mg/ml NTBC (100%) in the drinking water. All mice were bred in a pathogen-free facility 
and tested routinely for mouse diseases. Mice were also kept in temperature-and humidity-controlled animal 
quarters with a 12-h light-dark cycle. 
Animal ethics: Research involving animals complied with protocols approved by the Hamamatsu 
University School of Medicine Committee of Laboratory Animal Experimentation, Japan. 
Liver Cell Isolation and Transplantation: Mouse liver cells were isolated from 2- to 4-month-old male 
DsRed mice (The Jackson Laboratory) by two-step EDTA/collagenase perfusion using a protocol modified from 
Klaunig et al..7 In the isolation procedure, liver cell suspensions were centrifuged twice at 50X g to enrich for 
hepatocytes. Cell viability was determined by trypan blue exclusion and cells were selected for transplantation 
which were approximate  90% viable.  After isolation, liver cells were kept on ice and transferred within 2 hr. 
Liver cells (1-2x105) were transplanted into recipient mice of around 3 months of age by intrasplenic injection as 
described4. 
Western blotting for detection of homozygosity of Scid mice: About 200µl blood was collected from ~ 
24 gm of adult Fah-/-; Scid/Scid double knockout mice by using retro-orbital bleeding method as described 
earlier8. Blood was kept at room temperature for few minutes to hours for clotting and then centrifuged in order 
to collect sera. These sera were then subjected to western blotting as described earlier9. We described the western 
blotting procedure a little bit  details that the sera were separated by electrophoresis on 10% SDS-
polyacrylamide gel and transferred to a PVDF membrane (Cat. No. RPN2020F, GE Healthcare, 
Buckinghamshire, UK). The membranes were then incubated with the HRP-conjugated anti-mouse IgG (Cat. 
No. P0447, Dako, Glostrup, Denmark) antibodies. Finally, the signals of specific proteins were detected using 
the chemiluminescent ECL kit (Cat. No. NEL 104, NEL 105, Perkin-Elmer Life Sciences, MA, USA). 
Immunohistochemistry: Liver tissues were excised from ~4 month-old of Fah-/-; Scid/Scid double 
knockout mice after exogenous hepatocyte transplantation and frozen in OCT compound immediately (Tissue 
Tech, Torrance, CA, USA) for liver sectioning.  The 4μm thickness of liver sections were prepared. The sections 
were then rinsed with PBS and counter-stained with DAPI, and observed with a confocal microscope FV-1000 
(Olympus). 
 
3. Results 
Generation of Fah-/-; Scid/Scid double knockout mice: In order to generate the Fah-/-; Scid/Scid double 
knockout mice, we  crossed the Fah-/-  mice with the mice homozygous for the severe combined immune 
deficiency spontaneous mutation Prkdcscid, commonly referred to as scid characterized by an absence of 
functional T cells and B cells. Finally, we got eight desired mice by crossing with maintaining the following   
figure-1 and these mice were used for receiving the primary hepatocytes from DsRed mice. 
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Figure-1. Generation Fah-/-; Scid/Scid mice 
 
Detection of Fah genotype and homozygosity of scid in Fah-/-;Scid/Scid mice: 
Heterozygous and homozygous mice of  fah genotype were identified by genotyping of tail DNA (Figure 2). 
Genotyping was done with the same primers and conditions as described elsewhere6 or according to the 
protocols provided by vendors.  
 
 
Figure-2. PCR for fah genotype with tail DNA isolated fromdifferent mice. Band size 809 bp and band size 
433 bp indicated for wild type and fah gene mutant mice respectively. Lanes1 through 3 for wild type mice, 
lanes 4 through 10 for heterozygous mice for fah gene; lane11,1-kb Plus DNA ladder (Invitrogen) used as a 
molecular size marker. 
We next determined the homozygosity of Scid (Figure-3) in recipient Fah-/-;Scid/Scid mice by Western 
blotting as described in materials and methods section.   
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Figure-3. Western blotting for detection of IgG heavy and light chains for Scid homozygosity in recipient 
Fah-/-;Scid/Scid mice. Lanes 3, 5 and 8 indicated the homozygosity of Scid mice; lanes 2, 4, 6 and 7 indicated 
either wild type and heterozygous mice. Lane 1 indicated the prestained protein ladder (Wako, Japan). 
 
Detection of transplanted DsRed mice hepatocytes into Fah-/-;Scid/Scid recipient mice:  
For transplantation of DsRed mouse hepatocytes, we first generated a suitable immunodeficient mouse by 
crossing the Fah-/- mouse with the Scid mouse, which is depleted of mature B and T lymphocytes. These double 
knock-out mice allow more efficient engraftment of forign cells10. Hepatocytes from the DsRed mice were 
transplanted by intrasplenic injection11 into Fah-/-;Scid/Scid recipient mice. After transplantation, NTBC was 
withdrawn, and mice were monitored everyday for changes in body weight. A constant or increasing body 
weight reflects a balanced hydration status and is an indirect indicator of successfull engraftment. Fah-/-
;Scid/Scid  mice that did not receive hepatocyte transplantation and are withdrawn from NTBC progressively 
lose weight and die within 30-35 days. DsRed positive hepatocytes could be detected from periportal to 
centrilobular over the whole liver acinus in all liver lobes (Fig. 4A and 4B). DsRed cells were found in small 
clusters, reflecting the selective expansion after successful engraftment. 1.5 months after transplantation, some 
areas of the Fah-/-;Scid/Scid murine liver had 20% DsRed hepatocytes (Fig. 4A and 4B). 
 
Figure-4. DsRed mouse hepatocyte transplantation into recipient Fah-/-;Scid/Scid mice. (A) & (B) 
DsRed mouse hepatocyte clusters (Red fluorescent) are found over the entire left lower lobe of recipient mice 
liver. The liver sections were counter-stained with DAPI (blue). Photographs were obtained at 100X and 200X 
magnifications for 4A and 4B respectively. 
 
Survival rate and weight gain in Fah-/-;Scid/Scid recipient mice post exogenous hepatocyte transplantation 
and withdrawing NTBC water:  
In hereditary tyrosinaemia type I (HT1) (McKusick 276700), fatal liver disease results either because of liver 
failure during infancy or early childhood or because of development of hepatocellular carcinoma during 
childhood or adolescence. This is caused by toxic metabolites which accumulate because of deficiency of 
fumarylacetoacetase (Fah), the last enzyme in the tyrosine catabolic pathway.  2-(2-nitro-4-
trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC)  is a potent inhibitor of 4-hydroxyphenylpyruvate 
dioxygenase and has been shown to efficiently prevent tyrosine degradation, and production of succinylacetone, 
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in patients with tyrosinaemia12.The triketones such as NTBC, mesotrione acts as a herbicides which has been 
proposed for the treatment of Type 1 hereditary tyrosinaemia. Inhibition of  p-hypodroxylphenylpyruvate 
dioxygenase (HPPD) prevents production of homohentistic acid and the resulting accumulation of toxic products 
in patients with a Fah deficiency. Thus, NTBC has replaced the liver transplantation as the first line treatment for 
HT113.  
After transplantation, NTBC was withdrawn, and mice were monitored every second day for changes in 
body weight. A constant or increasing body weight reflects a balanced hydration status and is an indirect 
indicator of successful engraftment. Fah-/-;Scid/Scid mice thatdid not receive hepatocyte transplantation and are 
withdrawn from NTBC progressively lose weight and die within 30-35 days. We performed transplantation of 
DsRed mouse hepatocytes into 15 of  Fah-/-:Scid/Scid mice. In all cases, mice become very weak gradually after 
transplantation. Their weight decreased day by day. Ten of them died just after 30-35 days after withdrawing 
NTBC water. Finally,  we observed that five of the transplanted mice were looking healthy and also their body 
weight was increased and sometimes constant (Table 1). So, we have found that the survival rate is 33.33% after 
transplantation of DsRed hepatocytes. Even after 45 days, the mice were very good looking without NTBC 
water. Finally, we isolated the hepatocytes on 45th day after transplantation and performed fluorescence 
microscopy (Figure A and 4B). 
Table 1. Mouse weight observation after exogenouse hepatocyte transplantation 
No. of 
mice 
Sex Age on NTBC 
withdrawing 
and hepatocyte  
transplantation 
date 
Properties of 
mice 
Mouse weight (gm) on 
NTBC withdrawing and 
hepatocyte 
transplantation date 
Mouse weight (gm) on 
the 45th days after 
hepatocyte 
transplantation 
05 ♂ ~ 3 months Fah-/-;Scid/Scid 24.01±0.64 23.8±0.55 
 
4. Discussion: 
We report the development of a method for successful transplantation of hepatocytes from DsRed mice into Fah-
/-:Scid/Scid mice. The recipient mice lacked to produce fumarylacetoacetase enzyme. This is caused by toxic 
metabolites which accumulate because of deficiency of fumarylacetoacetase (Fah), the last enzyme in the 
tyrosine catabolic pathway. NTBC  is a potent inhibitor of 4-hydroxyphenylpyruvate dioxygenase and has been 
shown to efficiently prevent tyrosine degradation, and production of succinylacetone, in patients with 
tyrosinaemia.12  The recipient mice also lacked to produce B cells, T cells, and any residual NK cell activity. 
This property enhances the transplantation rate in recipient mice.Our transplantation success rate was 33.33%. 
To extend the usefulness of the Fah-/- knockout mouse model for studying liver cell growth, we crossed the 
Fah-/-  mice with the immunodeficient Scid mice to generate Fah-/-;Scid/Scid double knockout mice. 
Transplantation of liver cells from DsRed mice into these mice resulted in 20%  reconstitution of mouse liver 
with DsRed hepatocytes and even these knockout mice can be survived after withdrawing NTBC water. This is a 
good sign for the treatment of hereditary tyrosinaemia type I. This is also a remarkable demonstration that a 
functional liver can be formed from transplanted hepatocytes and suggests that Fah-/- knockout mouse livers can 
be reconstituted with hepatocytes from a range of species.  
 
5. Conclusion 
In conclusion, we demonstrate that the Fah-/-; Scid double knockout mouse is a suitable recipient for hepatocyte 
transplantation. If we are able to transplant human hepatocytes in these knockout mice, then these mice 
reconstituted with human hepatocytes can offer the opportunity to study drug metabolism and pursue gene 
therapy strategies. 
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